With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, ...

Cambridge still has the region’s lowest lab vacancies despite the life science industry slump, prompting a leading developer ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

A 1975 meeting at the Asilomar Conference Center in Pacific Grove, California, shaped a new safety regime for recombinant DNA ...

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

For nearly 20 years, a school in Cambridge, Massachusetts has been teaching people the art of glass blowing, introducing many to a new hobby. At the NOCA Glass School in North Cambridge ...

Massachusetts is in the midst of prosecuting ... devoted whole articles to outing particular customers, one being a Cambridge city councilor. Americans like to pretend that we're way more ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic ...